

Special Issue

Omics Data for Cancer Therapies: From Molecular Profiling to Clinical Applications

Message from the Guest Editor

The rapid advancement of high-throughput omics technologies—including genomics, transcriptomics, epigenomics, proteomics, and metabolomics—has significantly reshaped our understanding of cancer biology. These data-rich approaches are instrumental in identifying biomarkers, elucidating mechanisms of resistance, uncovering novel therapeutic targets, and supporting the development of precision oncology. This Special Issue will bring together original research articles and comprehensive reviews that leverage omics data to advance cancer therapies. We invite submissions that explore integrative analyses, the data-driven discovery of therapeutic vulnerabilities, biomarker identification, personalized treatment strategies, and the translational potential of multi-omics data. We particularly encourage studies that utilize publicly available or large-scale clinical datasets, apply innovative computational approaches, or address the challenges of integrating omics data into clinical decision-making.

Guest Editor

Dr. Luciano Cascione

1. Institute of Oncology Research, Faculty of Biomedical Sciences, Università della Svizzera Italiana, 6500 Bellinzona, Switzerland
2. Swiss Institute of Bioinformatics, 1015 Lausanne, Switzerland

Deadline for manuscript submissions

31 October 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/239390

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)